Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, discusses a Phase II study exploring the use of parsaclisib, a PI3Kdelta inhibitor in myelofibrosis patients that show suboptimal responses to ruxolitinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

свернуть